



GP 1800  
P/42-60

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Fabrizio Sgarritani, et al.

Serial No. 08/737,633

Filed November 15, 1996

Date: July 30, 1997

Group Art Unit: 1812

Examiner: M. Ranjan

For: IFN-BETA LIQUID FORMULATIONS

AMENDMENT TRANSMITTAL LETTER - FEE COMPUTATION

Hon. Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Transmitted herewith is an amendment in the above-identified application.

\_\_\_\_\_ "Small Entity" status (37 C.F.R. §1.9 & §1.27) established  
\_\_\_\_\_ previously \_\_\_\_\_ by enclosed verified statement.

OFGS Check No. \_\_\_\_\_, which includes the fee of \$ -0- calculated below, is attached.

NO. CLAIMS AFTER AMENDMENT	HIGHEST NO. PREVIOUSLY PAID FOR	EXTRA PRESENT	RATE	ADDIT. FEE
TOTAL	MINUS 20	* =	x (\$11 SE or \$22)	\$
INDEP.	MINUS 3	** =	x (\$40 SE or \$80)	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			x (\$130 SE or \$260)	\$
* not less than 20 ** not less than 3			TOTAL \$	

In the event the actual fee is greater than the payment submitted or is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 15-0700.

If this communication is filed after the shortened statutory time period had elapsed and no separate Petition is enclosed, the Commissioner of Patents and Trademarks is petitioned, under 37 C.F.R. §1.136(a), to extend the time for filing a response to the outstanding Office Action by the number of months which will avoid abandonment under 37 C.F.R. §1.135. The fee under 37 C.F.R. § 1.17 should be charged to our Deposit Account No. 15-0700.

Respectfully submitted,

*Edward A. Meilman*

Edward A. Meilman

Registration No.: 24,735

OSTROLENK, FABER, GERB & SOFFEN, LLP

1180 Avenue of the Americas

New York, New York 10036

Telephone: (212) 382-0700

EAM:od



#6/43  
P/42-60 (PCT)  
ifh  
8/22/97

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent Application of

Samaritani, et al.

Serial No. 08/737,633

Filed: November 15, 1996

For: IFN-BETA LIQUID FORMULATIONS

Date: July 30, 1997

Group Art Unit: 1812

Examiner: M. Ranjan

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

RECEIVED  
AUG 21 1997  
GP

AMENDMENT

Sir:

In response to the Office Action dated May 13, 1997,  
please reconsider the above-identified application amended as  
follows:

IN THE SPECIFICATION:

Please amend the specification as follows:

Page 1, line 12, after "forms", insert --,--; and  
line 13, after "anti-viral", insert  
--activity--.

Page 6, line 7, after "beaker", insert --,--.

IN THE ABSTRACT

Please delete the Abstract in its entirety and  
substitute therefor the Abstract attached hereto.